Trial reportJournal of clinical psychopharmacology2014
Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
Trial report in Journal of clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.Translational psychiatry · 2024Pooled it
- ERICH3: vesicular association and antidepressant treatment response.Molecular psychiatry · 2021Pooled it
- Social inequalities in antidepressant treatment outcomes: a systematic review.Social psychiatry and psychiatric epidemiology · 2020Pooled it
- New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.The pharmacogenomics journal · 2018Pooled it
- Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting.European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- Clinical utility of pharmacogenetics in a psychiatric and primary care population.The pharmacogenomics journal · 2023Trial
- Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.Translational psychiatry · 2019Trial
- Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.Medicina (Kaunas, Lithuania) · 2026Article
- Predicting remission after acute phase pharmacotherapy in patients with bipolar I depression: A machine learning approach with cross-trial and cross-drug replication.Bipolar disorders · 2025Article
- Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation.medRxiv : the preprint server for health sciences · 2023Article
- Precision Medicine in Antidepressants Treatment.Handbook of experimental pharmacology · 2023Review
- The role of pharmacogenetics in the treatment of major depressive disorder: a critical review.Frontiers in psychiatry · 2023Review
- Identifying the Common Genetic Basis of Antidepressant Response.Biological psychiatry global open science · 2022Article
- Chronic cortisol differentially impacts stem cell-derived astrocytes from major depressive disorder patients.Translational psychiatry · 2021Article
- Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.Translational psychiatry · 2021Article
- Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.Translational psychiatry · 2021Article
- DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results.Pharmacogenomics and personalized medicine · 2021Article
- Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.Clinical pharmacology and therapeutics · 2020Article
- Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.Journal of affective disorders · 2020Article
- Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder.Frontiers in psychiatry · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
Abstract
backgroundThe effectiveness of selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder (MDD) is controversial.
aimsThe clinical outcomes of subjects with nonpsychotic MDD were reported and compared with the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study outcomes to provide guidance on the effectiveness of SSRIs.
methodsSubjects were treated with citalopram/escitalopram for up to 8 weeks. Depression was measured using the Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) and the 17-item Hamilton Depression Rating Scale.
resultsThe group of subjects with at least 1 follow-up visit had a remission (QIDS-C16 ≤ 5) rate of 45.8% as well as a response (50% reduction in QIDS-C16) rate of 64.8%, and 79.9% achieved an improvement of 5 points or higher in QIDS-C16 score. The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study subjects were more likely to achieve a response than STAR*D study subjects. After adjustment for demographic factors, the response rates were not significantly different. When reporting the adverse effect burden, 60.5% of the subjects reported no impairment, 31.7% reported a minimal-to-mild impairment, and 7.8% reported a moderate-to-severe burden at the 4-week visit.
conclusionsPatients contemplating initiating an SSRI to treat their MDD can anticipate a high probability of symptom improvement (79.9%) with a low probability that their symptoms will become worse. Patients with lower baseline severity have a higher probability of achieving remission. The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study replicates many findings of the first phase of the STAR*D study after controlling for the differences between the studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.